A First-in-human Trial of Autologous Induced Pluripotent Stem Cells (iPSC)-Derived Islets: Developing a Personalized Diabetes Therapy

自体诱导多能干细胞 (iPSC) 来源的胰岛的首次人体试验：开发个性化糖尿病疗法

• 批准号: 454362
• 负责人: Shapiro James
• 金额: $ 72.85万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-07-01 至 2026-07-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=454362&lang=en
• 关键词: Autoimmunity; Autologous Human Ipscs; Beta Cell Replacement Therapy; Cell Replacement Therapy; Clinical Trial; Diabetes Treatment; Induced Pluripotent Stem Cells; Islet Transplantation; Personalized Cell Therapy; Stem Cell Biology

Diabetes is caused by the lack of insulin, a hormone produced by the islet Beta-cells in the pancreas that regulates blood sugar. Chronically high blood sugar can cause complications such as blindness, amputations, stroke, heart disease, kidney failure an

糖尿病是由于缺乏胰岛素引起的，胰岛素是由胰腺中的胰岛β细胞产生的一种调节血糖的激素。长期高血糖会导致失明、截肢、中风、心脏病、肾衰竭等并发症